Pharmacology, Toxicology and Pharmaceutical Science
Bisphosphonic Acid Derivative
100%
Cohort Study
83%
Hip Fracture
75%
Fragility Fracture
67%
Alendronic Acid
33%
Disease
28%
Vitamin D
25%
Denosumab
24%
Comorbidity
24%
Spine Fracture
21%
Femur Fracture
20%
Replacement Therapy
20%
Mortality
18%
Prevalence
17%
Adverse Event
16%
Glucocorticoid
16%
Randomized Controlled Trial
15%
Forearm Fracture
13%
Proton Pump Inhibitor
12%
Cross-Sectional Study
11%
Primary Hyperparathyroidism
11%
Parathyroid Hormone
11%
Observational Study
10%
Chronic Kidney Failure
9%
Prostate Cancer
9%
Malignant Neoplasm
9%
Osteogenesis Imperfecta
9%
Drug Holiday
8%
Case-Control Study
8%
Receptor
8%
Osteoprotegerin
7%
Osteoarthritis
7%
Atrial Fibrillation
7%
Pathophysiology
7%
All Cause Mortality
7%
Thyrotropin
7%
Hypothyroidism
7%
Cardiovascular Risk
6%
Oncogenic Osteomalacia
6%
Cardiovascular Disease
6%
Clinical Trial
6%
Biochemical Marker
6%
Zoledronic Acid
6%
Non Insulin Dependent Diabetes Mellitus
6%
Multiple Chronic Conditions
5%
Inflammation
5%
Risk Evaluation
5%
Pharmacotherapy
5%
Diabetes Mellitus
5%
Musculoskeletal Disease
5%
Medicine and Dentistry
Osteoporosis
68%
Cohort Analysis
65%
Hip Fracture
53%
Fragility Fracture
46%
Bone Density
40%
Bisphosphonate
40%
Cohort Effect
25%
Drug Therapy
23%
Vitamin D
22%
Hip
22%
Alendronic Acid
21%
Disease
17%
Polycystic Ovary Syndrome
15%
FRAX
14%
Systematic Review
14%
Osteogenesis Imperfecta
13%
Primary Hyperparathyroidism
13%
Comorbidity
13%
Prevalence
13%
Postmenopause
12%
Bone Mass
12%
Hazard Ratio
12%
Spine Fracture
11%
Cardiovascular System
11%
Femur Fracture
11%
Parathyroid Hormone
11%
Isotopes of Calcium
10%
Osteolysis
10%
Diabetes
9%
Mortality
9%
Case-Control Study
9%
Parathyroidectomy
9%
Risk Evaluation
9%
Randomized Controlled Trial
8%
Population
8%
Cross Sectional Study
8%
Bone Turnover
8%
Cardiovascular Disease
8%
Fracture
7%
Dual-Energy X-Ray Absorptiometry
7%
Observational Study
7%
Denosumab
7%
Messenger RNA
7%
Osteoarthritis
7%
Forearm Fracture
7%
Primary Health Care
6%
Oncogenic Osteomalacia
6%
Osteoprotegerin
6%
Glucocorticoid
6%
Proton-Pump Inhibitor
6%
Nursing and Health Professions
Hip Fracture
32%
Bone Density
20%
Bisphosphonic Acid Derivative
18%
Cohort Analysis
18%
Drug Therapy
17%
Fragility Fracture
16%
Confidence Interval
10%
Mortality
9%
Spine Fracture
8%
Primary Medical Care
7%
Dual Energy X Ray Absorptiometry
7%
Hazard Ratio
6%
Comorbidity
6%
Osteoarthritis
5%
Bone Mass
5%
